Financial Disclosure

Delray Beach – October 02, 2026 -- The global emulsifiers market is projected to climb to USD 18.15 billion by 2031, up from USD 12.15 billion in 2026, expanding at a compound annual growth rate of 8.4%, according to MarketsandMarkets.

Food applications drive demand as processed food consumption rises worldwide

Food emulsifiers are set to post the fastest growth within applications, at an 8.9% CAGR, as manufacturers use the ingredients to stabilize bakery goods, dairy products, margarine, sauces, and plant-based foods. Rising demand for low-fat, low-calorie, and clean-label products is pushing producers to rely on emulsifiers to maintain texture and shelf life without added fats or calories.

Vancouver – October 02, 2026 -- Trilogy Metals Inc. (NYSE American: TMQ; TSX: TMQ) closed a $17.8 million strategic equity investment from the United States Department of War (DOW) on September 11, 2026, as part of a broader $35.6 million financing package tied to its Upper Kobuk Mineral Projects (UKMP) in Alaska. The company reported a cash balance of $31.2 million and adjusted working capital of $30.3 million as of August 31, 2026, which it says substantially funds its share of Ambler Metals LLC's fiscal 2026 budget.

Delray Beach, Fla. – October 02, 2026 -- The global space sensors and actuators market is set to grow from $5.75 billion in 2026 to $9.04 billion by 2031, a 9.5% compound annual growth rate, according to a new report from MarketsandMarkets.

Sensors segment leads demand on satellite positioning and propulsion needs

By product type, sensors are estimated to lead the market, driven by their critical role in satellite positioning, propulsion control, and robotic operations. Manufacturers are advancing compact, radiation-hardened, and electromechanical sensor designs to serve both deep space and commercial missions.

Interplanetary spacecraft and probes dominate platform-level spending

The interplanetary spacecraft & probes segment is estimated to hold the largest market share by platform, as rising investment in planetary exploration missions fuels demand for advanced sensing and actuation systems.

Kilmarnock – October 02, 2026 -- Copenhagen Infrastructure Partners (CIP) has taken a Financial Investment Decision for Kilmarnock South, a 350 MW/1,400 MWh lithium-ion battery energy storage system in south Ayrshire, Scotland, committing over EUR 270 million (GBP 232 million) through its fourth flagship fund, Copenhagen Infrastructure IV.

Construction begins with commercial operations targeted for Q1 2028

Kilmarnock South is now under construction and is scheduled to reach commercial operations in the first quarter of 2028. At four hours of duration, it will become the longest-duration asset in CIP's UK storage portfolio once operational, designed to store surplus Scottish wind power and release it to the grid during periods of network capacity.

Stockholm – October 02, 2026 -- Skanska has signed an additional USD 60 million (SEK 560 million) contract with Lee Health for the construction of a new hospital and medical office building in Fort Myers, Florida. The sum will be booked in Skanska's US order intake for the third quarter of 2026.

Contract amendment covers interior and mechanical work for bed tower expansion

The amendment adds interior build-out finishes and mechanical, electrical and plumbing work tied to the project's West Bed Tower expansion. It builds on the original full project agreement between Skanska and Lee Health.

Full project scope totals roughly 50,200 square meters of hospital and medical office space

The complete contract scope includes a five-story hospital of approximately 38,600 square meters (416,000 square feet), a central energy plant, and an 11,600-square-meter (125,000-square-foot) medical office building that houses an ambulatory surgery center.

Los Angeles – October 02, 2026 -- FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) showcased the EAI Robotics business of Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) at IROS 2026 in Pittsburgh, Pennsylvania, held September 28-30, 2026, as the two companies advance a non-binding term sheet that values the robotics unit at approximately $200 million.

All-New Futurist robot draws most attendee interest at Pittsburgh conference

FF displayed multiple EAI robot products built on its "One-Brain Multi-Form Multi-Capability" EAI Robot World 2.0 architecture. The All-New Futurist unit attracted particular attention for its mobile operation and flexible task execution across demonstrated scenarios. The company also introduced its "Built in USA" Acceleration Program during the three-day event, one of the largest robotics research conferences globally.

Stockholm – October 02, 2026 -- Skanska has signed a USD 271 million (approximately SEK 2.5 billion) contract with NAVFAC Mid-Atlantic to construct a new homeport pier at Naval Station Newport in Newport, Rhode Island. The deal will be booked in Skanska's U.S. order intake for the third quarter of 2026.

New Pier Replaces Aging Infrastructure at Active Navy Installation

The project calls for the demolition of the existing Pier 1, which measures approximately 30 meters by 482 meters (100 feet by 1,580 feet). In its place, Skanska will build a smaller, modern pier spanning roughly 24 meters by 305 meters (80 feet by 1,000 feet), engineered to berth four U.S. Coast Guard Offshore Patrol Cutters.

London – October 02, 2026 -- Samfara has completed the acquisition of Chr. Olesen Synthesis, a Danish manufacturer of controlled-substance active pharmaceutical ingredients, marking the London-based life sciences investment firm's first deal. The transaction sees Samfara buy the business from Chr. Olesen and funds managed by Signet Healthcare Partners, with Chief Executive Thomas Moestrup co-investing alongside the new owner. Financial terms were not disclosed.

Chr. Olesen Synthesis supplies opioid-disorder and ADHD treatment ingredients globally

Based near Copenhagen, Chr. Olesen Synthesis develops and manufactures APIs and advanced intermediates specialising in controlled substances, including buprenorphine for opioid use disorder and lisdexamfetamine for ADHD. Its cGMP-certified plant in Hvidovre has been in commercial production since 2015, supplying pharmaceutical companies across Europe, North America and the Middle East.

Suzhou – October 02, 2026 -- Novartis has agreed to pay Abogen Biosciences an upfront fee of USD 575 million to secure worldwide rights to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager for autoimmune diseases, with total deal value reaching up to approximately USD 7.2 billion if all milestones and options are exercised.

Novartis secures exclusive worldwide license to Abogen's lead autoimmune asset ABO2203

The licensing and option agreement grants Novartis an exclusive global license to ABO2203, which Abogen describes as the first mRNA-encoded T-cell engager to enter clinical evaluation for autoimmune diseases. The molecule uses mRNA to direct endogenous production of T-cell engagers in vivo, targeting B-cell depletion through a mechanism the companies say differs from traditional recombinant T-cell engagers.

Toronto – October 02, 2026 -- Manulife Financial Corporation has closed a reinsurance transaction transferring biometric risk on a block of long-term care policies carrying $3.2 billion in reserves to Munich American Reassurance Company, a US subsidiary of Munich Re Group.

Manulife offloads $3.2 billion in long-term care reserves to Munich Re Life US

The deal shifts biometric risk exposure tied to the long-term care block off Manulife's balance sheet and onto Munich Re Life US, a subsidiary specializing in life and disability reinsurance for North American carriers. The transaction was first announced on October 02, 2026, and has now reached formal closing.